Ocular Allergy Treatment Practical Impact Trial

Status unconfirmed · Phase 4

Conditions studied: Allergic Conjunctivitis, Rhinoconjunctivitis

In brief

To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.

Key facts

Study ID

NCT01808768

Run by

Starx Research Center, LLC

People needed

50

Starts

2013-04-01

Expected to finish

2013-11-01

Last updated by the study team

2013-05-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients age 18 and older with a history of seasonal or perennial forms of allergic conjunctivitis and skin test positive reactivity to seasonal aeroallergens
• Total Ocular Symptom Score (TOSS) on the day of enrollment of 4 or more.
• have allergic ocular symptoms for the past week for which they are either treating with ophthalmic agents or have had no treatment.
• Are willing/able to follow instructions from the study investigator and his/her study staff.
• Have signed infromed consent approved by Institutional Review Board or Independent Ethics Committee.

You may not qualify if…

• Active ocular infection;
• History of retinal detachment, diabetic neuropathy, or any progressive retinal disease;
• Ocular surgical intervention within three (3) months prior to visit 1 or scheduled during the study.
• History of unstable, or uncontrolled disease of any nature.
• Pregnancy or lactation;
• Have a known hypersensitivity tp LASTACAFT™ (alcaftadine) -

Where it is running

• STARx Research Center — Edison, New Jersey, United States (enrolling)
• STARx — Springfield, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.